Drug Approval | July 27, 2025
Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Revenue increased 11.4 per cent to Rs. 8,545 crore
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Subscribe To Our Newsletter & Stay Updated
